MARKET

CALC

CALC

CALCIMEDICA INC
NASDAQ
0.9309
-0.0561
-5.68%
Opening 14:55 06/30 EDT
OPEN
0.9487
PREV CLOSE
0.9870
HIGH
0.9744
LOW
0.8500
VOLUME
559.78K
TURNOVER
--
52 WEEK HIGH
7.20
52 WEEK LOW
0.4606
MARKET CAP
14.71M
P/E (TTM)
-0.7220
1D
5D
1M
3M
1Y
5Y
1D
CalciMedica Insider Makes Bold Move With Fresh Stock Buy
TipRanks · 21h ago
Monday 6/29 Insider Buying Report: ADBE, CALC
NASDAQ · 1d ago
CalciMedica director Fred A. Middleton acquires 248,972 common shares worth $200,000
PUBT · 1d ago
Weekly Report: what happened at CALC last week (0622-0626)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 4d ago
CalciMedica Advances Auxora After Favorable FDA Safety Review
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC)
TipRanks · 6d ago
More
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Webull offers Calcimedica Inc stock information, including NASDAQ: CALC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CALC stock methods without spending real money on the virtual paper trading platform.